ADDNVAX | Linksium
Back to portfolio



A “plug&display” and multimeric protein vaccine platform

profilePhoto   Laurène El Bahhaj
Linksium Contact Laurène El Bahhaj +33 (0)7 76 23 29 19
Image addnvax


  • Thermostable
  • Ease of delivery and storage
  • Quickly adaptable
  • Quick response to emerging diseases

Key words

  • Autoassembling plateform
  • Multimeric
  • Plug & Display
  • Infectious diseases

Intellectual Property

  • 1 patent


  • IBS


  • CEA
  • CNRS
  • UGA

Linksium Continuum

  • Maturation
  • Incubation


The COVID-19 pandemic clearly shows how emergent diseases can cause severe global health and economic problems. We must be prepared to react swiftly against new pathogenic agents and this requires the development of vaccines that are safe, efficient in the long-term and easily adaptable with a short revision time.


The technology is based on a 60-mer self-assembling protein derived from an adenoviral protein. The platform has been genetically modified to express a superglue system on its surface. This innovation allows the multimeric presentation of different antigens of interest even of large size.


The thermostability of the platform allows for the production of batches that can be stored over the long term. This represents a strategic advantage in order to be ready to respond rapidly to the emergence of infectious diseases.

State of progress

Various proofs of concept have been developed in the infectious disease domain on the establishment of candidate vaccines against SARS-CoV 2 and yellow fever virus. In addition, ADDnVaX has extended its scope to cancer vaccines, tested against melanoma.


  • Emerging diseases and zoonoses
  • Infectious diseases
  • Immunotherapies (cancer...)